BMT CTN Protocol 0402
A Phase III Randomized, Multicenter Trial Comparing
Sirolimus/Tacrolimus with Tacrolimus/Methotrexate as GVHD Prophylaxis
After HLA-Matched, Related Peripheral Blood Stem Cell Transplantation
Below are protocol-related documents, which may be periodically updated.
- Protocol synopsis, version 4.0 dated December 3rd, 2010
- Protocol, version 4.0 dated December 3rd, 2010
- Consent forms, version 4.0 dated December 3rd, 2010
- Summary of changes from version 3.0 to version 4.0
- Educational Material
- Participating centers
- This study is posted on clinicaltrials.gov as NCT00406393
- Key Personnel
Protocol Co-Chair: Joseph Antin, MD (617-632-2525) jantin@partners.org
Protocol Co-Chair: Corey Cutler, MD (617-632-5946) cscutler@partners.org
Protocol Officer: Marcelo Pasquini, MD (414-805-0700) mpasquin@mcw.edu
Protocol Coordinator: Kristin Knust (301-251-1161) kknust@emmes.com
Medical Monitor: Mary Eapen, MD (414-805-0700) meapen@mcw.edu
This study will close to new patient accrual on October 28, 2011; therefore, site participation application are no longer being accepted.
